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Examination of signaling pathways used by HTLV-1-infected rabbit cell lines revealed differences between one, RH/K30,
that mediates asymptomatic infection and another, RH/K34, that causes lethal experimental leukemia. Both lines are IL-2
independent; RH/K30 produces IL-4 while RH/K34 produces IL-10. Examination of the Jak/STAT (Janus kinase/signal
transducer and activator of transcription) activation of the lines revealed constitutive phosphorylation of Jak1 in both. STAT6
phosphorylation, not previously reported for HTLV-1 cells, was observed in RH/K30; STAT1 and STAT3 were phosphorylated
in RH/K34. Treatment with cytokines altered the activation of the STAT proteins: IL-2 induced STAT5 phosphorylation in both
lines. Supernatant from RH/K34 or IL-10 induced STAT3 phosphorylation in RH/K30 cells. Supernatant from RH/K30 or IL-4
induced STAT6 phosphorylation in RH/K34 cells, which could be reversed with a Jak kinase inhibitor—AG-490.
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The human retrovirus HTLV-1 infects 10–20 million
people worldwide. While 95% of infected people remain
lifelong asymptomatic carriers of the virus, approximately
5% develop HTLV-1-associated disease (Bangham,
2000). HTLV-1 causes a highly fatal T-cell malignancy,
adult T-cell leukemia/lymphoma (ATLL), and a variety of
chronic inflammatory syndromes, of which HTLV-1-asso-
ciated myelopathy/tropical spastic paraparasis (HAM/
TSP) is the most notable (Franchini, 1995). The mecha-
nisms of the variable pathogenicity induced by this ret-
rovirus are not clear, though the availability of infectious
molecular clones and practical animal models has al-
lowed elucidation of the important functions of the viral
proteins in the life cycle, in T-cell transformation, and in
in vivo infectivity (Franchini, 1995).
Our studies have used two HTLV-1-transformed rabbit
T-cell lines to investigate factors involved in viral patho-
genicity: RH/K30 mediates asymptomatic infection and
RH/K34 causes a fatal leukemia-like disease within 10
days after injection of the rabbits (Simpson et al., 1996).
Comparison of proviral nucleotide sequences from the
two cell lines revealed greater than 99% identity, which
suggests that the structure of the integrated virus is not
the sole factor in the ability of RH/K34 to cause ATLL-like
disease (Zhao et al., 1993). Studies with infectious mo-
lecular clones and chimeric clones derived from these
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91cell lines have identified genetic regions important to in
vivo or in vitro virus production (Zhao et al., 1995, 1996).
The relationship between infectivity of virus constructs
and the pathogenesis produced by the infected cells
remains obscure. Initial assessments of cytokine pro-
duction and cell protein phosphorylation revealed differ-
ences between the two cell lines. RH/K30 does not
produce IL-10, while RH/K34 does; both cells express the
receptor for IL-10 (IL-10R) (Kindt et al., 1999). These
findings suggest that differences in the activation state of
molecules involved in critical signaling pathways may be
important to the functional differences of the cell lines.
The presence of high levels of the IL-2 receptor alpha
chain (IL-2Ra) is a common feature of ATLL cells and
HTLV-1-transformed cell lines (Franchini, 1995). One of
the well-documented signaling pathways mediated by
IL-2R is Jak/STAT. Under physiological conditions, activa-
ion of the Jak/STAT proteins is triggered by cytokine
inding to its cell surface receptor. This is followed by
he phosphorylation of Jak proteins and the subsequent
yrosine phosphorylation of the cytokine receptor. The
hosphorylated tyrosine residues in the receptor provide
docking site for STAT proteins. The bound STAT protein
s phosphorylated by the receptor-associated Jak kinase.
fter phosphorylation, STAT proteins dimerize and trans-
ocate to the nucleus to activate transcription of down-
tream genes, leading to an altered cell phenotype (Dar-
ell, 1997; Heim, 1999). Abnormal activation of the STAT
roteins is a common characteristic of leukemias (Lin et
l., 2000). Constitutive activation of the IL-2R–Jak3/STAT5
ignaling pathway is correlated with IL-2 independence
f HTLV-1-transformed cell lines (Xu et al., 1995; Migone
0042-6822
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92 LIANG ET AL.et al., 1995; Mulloy et al., 1998). Similarly, a study with
ncultured ex vivo leukemic cells from HTLV-1 seropos-
tive patients with ATLL also displayed constitutive acti-
ation of Jak3, STAT1, STAT3, and STAT5 (Takemoto et al.,
997). These results suggest that activation of the IL-2R
ignaling pathway mediated by Jak/STAT may play a key
ole in transformation by HTLV-1.
The present study concerns the Jak/STAT signaling
athway and the corresponding cytokines in the two
L-2-independent cell lines, RH/K30 and RH/K34. We
ound constitutive phosphorylation of STAT1 and STAT3
n RH/K34 cells, whereas in RH/K30 only STAT6 dis-
layed constitutive phosphorylation. In addition, IL-4 and
L-10, differentially expressed by RH/K30 and RH/K34,
ontrolled protein phosphorylation. These results sug-
est that the Jak/STAT pathways are intact in both the
ethal and the nonlethal HTLV-1 lines and that specific
TAT proteins are activated in response to cytokines
roduced by the two cell lines.
RESULTS
onstitutive phosphorylation of Jak/STAT proteins in
TLV-1-transformed T-cell lines
The Jak/STAT activation status of two rabbit HTLV-1
ell lines (RH/K30 and RH/K34) was tested and com-
ared to HTLV-1-infected (MT-2) and uninfected (A3.01)
uman T-cell lines. Cell lysates from the four cell lines
ere analyzed using antibodies specific for native or
yrosine-phosphorylated proteins of Jak1 and members
f the STAT family (STAT1, STAT3, STAT5, and STAT6). As
hown in Fig. 1A, Jak1 was tyrosine phosphorylated in
H/K30, RH/K34, and MT-2 but not in A 3.01 cells. STAT1
nd STAT3 were phosphorylated in RH/K34 and MT-2
ells, but not in RH/K30 cells. Unexpectedly, STAT5,
hich is normally activated in IL-2-independent lines,
as observed only in MT-2 cells, not in the rabbit cell
ines. STAT6 was tyrosine phosphorylated only in the
H/K30 cell line. None of the Jak/STAT proteins tested in
his experiment were phosphorylated in the HTLV-1-non-
nfected cell line, A3.01, although it expressed detectable
evels of each native protein. The nature of the activation
athways was further explored.
ak1 is associated with STAT1 and STAT3
Jak1, which was constitutively phosphorylated in both
ell lines, activates STAT1 and STAT3. Because neither
TAT1 nor STAT3 was activated in RH/K30, we examined
he association of Jak1 with STAT1, STAT3, and STAT6.
ak1 was immunoprecipitated with anti-Jak1 antibody
rom RH/K30 and RH/K34 cell lysates; the precipitates
ere analyzed by immunoblotting with STAT antibodies.
s shown in Fig. 1B, Jak1 coprecipitated with STAT1 and
TAT3 in both RH/K30 and RH/K34 cells, despite the
bsence of activated STAT1 or STAT3 in RH/K30. We
f
tould not coprecipitate STAT6 with Jak1 in either cell line
data not shown), suggesting that other kinases were
esponsible for the phosphorylation of STAT6.
xpression of cytokines and their receptors by
H/K30 and RH/K34 cells
The Jak/STAT signal transduction processes are initi-
ted by a variety of cytokines (Rane and Reddy, 2000) and
TLV-1 infection alters cytokine expression (Noma et al.,
989; Villiger et al., 1991; Mori et al., 1996; Azimi et al.,
998). Therefore, we determined the expression of cyto-
ines and receptors in RH/K30 and RH/K34 cells by
T-PCR and flow cytometric analysis.
Binding experiments using biotinylated human IL-4
nd IL-10 demonstrated that both cell lines express the
eceptors for IL-4 and IL-10 and can bind these cytokines
t comparable levels (Fig. 2A). RT-PCR (Fig. 2B) con-
FIG. 1. (A) Tyrosine phosphorylation status of Jak/STAT proteins in
HTLV-1-infected (RH/K30, RH/K34, and MT2) and noninfected (A 3.01)
cell lines. Lysates from the cell lines were subjected to electrophoresis
and immunoblotted with antibodies specific for native or tyrosine-
phosphorylated forms of the Jak/STAT proteins as indicated to the right
of each panel. (B) Jak1 is associated with STAT1 and STAT3. Jak1 was
immunoprecipitated with anti-Jak1 antibody in RH/K30 and RH/K34
cells. Association with STAT proteins was determined by immunoblot-
ting with STAT1 or STAT3 antibodies.irmed that only RH/K34 expressed the gene for IL-10 and
hat IL-4 was expressed only in RH/K30. RT-PCR also
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93CYTOKINE-INDUCED ACTIVATION OF HTLV-1 CELL LINESindicated that both RH/K30 and RH/K34 expressed the
IL-2Rgc gene (Fig. 2B). b-actin cDNA was PCR amplified
in the RT reactions to serve as an internal control (Fig.
2B). These data suggested that the cytokine expression
profile was different between the two lines although they
had similar cytokine receptor expression patterns.
Cytokine-inducible phosphorylation of STAT3 in RH/
K30 and STAT6 in RH/K34 cells
IL-10 is involved in the activation of STAT3, and IL-4
induces phosphorylation of STAT6 (Rane and Reddy,
2000). Because both lines express receptors for both
cytokines but express only one of them, the inductive
effect of IL-10 and IL-4 to stimulate the phosphorylation
of STAT proteins was tested. As shown in Fig. 3A, human
recombinant IL-10 induced the phosphorylation of STAT3
in RH/K30 cells but did not alter the phosphorylation level
of STAT3 in RH/K34 cells. We also demonstrated that IL-4
FIG. 2. Expression of IL-10 and IL-4 and cytokine receptors in HTLV-
-transformed cell lines. (A) FACS profiles of RH/K30 and RH/K34
howing binding of either biotinylated human IL-4 or biotinylated hu-
an IL-10 (depicted as boldface lines). Control fluorescence of the
ells is depicted as light lines. (B) Agarose gel separation of RT-PCR
roducts generated using primers for rabbit IL-4 (product size: 366 bp),
L-10 (product size: 348 bp), and human IL-2Rgc (product size: 1113 bp).
mplification of b-actin cDNA (product size: 218 bp) served as an
internal control. The MW marker in this experiment is 100-bp DNA
ladder.induced phosphorylation of STAT6 in RH/K34 cells but at
a lower level than achieved in similarly treated A3.01cells. Blots using antibodies for either STAT3 or STAT6
showed equivalent loading of the gels and confirmed
that the changes in tyrosine phosphorylation did not
reflect an increase in protein expression levels (Figs. 3A
and 3B, bottom). These results confirmed that the signal-
ing pathways were intact in the two cell lines.
Results similar to IL-4/IL-10 induction were obtained
using filtered supernatants from the two cell lines. As
shown in Fig. 3C, supernatant from RH/K34 cells induced
phosphorylation of STAT3 in RH/K30 cells. Conversely,
supernatant from RH/K30 cells induced phosphorylation
of STAT6 in RH/K34 cells within 1 h and the induction was
dose-dependent (Fig. 3D). These results indicate that the
specific phosphorylation of STAT proteins is induced by
different cytokines.
The time course of the stimulation of tyrosine phos-
phorylation of STAT3 and STAT6 was examined next.
RH/K30 cells or RH/K34 cells were stimulated for 5, 15,
30, 60, and 120 min with IL-10 or IL-4. As shown in Fig.
FIG. 3. Cytokine-induced tyrosine phosphorylation of STAT family
proteins in HTLV-1-transformed cell lines. (A) Detection of STAT3 and
tyrosine-phosphorylated STAT3 in cells lines untreated or treated with
IL-10 (100 ng/ml) by immunoblotting. (B) Detection of STAT6 and ty-
rosine-phosphorylated STAT6 in cells lines untreated or treated with
IL-4 (25 ng/ml) by immunoblotting. (C) RH/K30 cells were treated with
RPMI medium (lane 1) and 20% (lane 2), 50% (lane 3), or 100% (lane 4)
supernatant from RH/K34 cells for 1 h and native or phosphorylated
STAT3 was tested by immunoblotting. (D) RH/K34 cells were treated
with RPMI medium (lane 1), and 20% (lane 2), 50% (lane 3), or 100%
(lane 4) supernatant from RH/K30 cells for 1 h and native or phosphor-
ylated STAT6 was tested by immunoblotting.
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94 LIANG ET AL.4A, increased tyrosine phosphorylation of STAT3 in RH/
K30 was detected as early as 5 min after stimulation and
increased in a time-dependent manner until at least 120
min. The phosphorylation of STAT6 in RH/K34 was also
induced as early as 5 min after IL-4 stimulation and
reached its peak at 120 min (Fig. 4B). The phosphoryla-
tion of STAT6 persisted for as long as 24 h after stimu-
lation (data not shown). Neither IL-4- nor IL-10-induced
STAT phosphorylation reached the constitutive levels ob-
served in RH/K30 or RH/K34 cells.
Effect of IL-2 on phosphorylation of STAT proteins
Because IL-2 plays a key role in HTLV-1 transforma-
tion, the effects of this cytokine were tested. Both RH/K30
and RH/K34 cells are IL-2-independent and express nei-
ther IL-2 nor phosphorylated STAT5. Addition of exoge-
nous IL-2 induced phosphorylation of STAT5 in both lines
with higher levels in RH/K34 cells (Fig. 5A). IL-2 did not
induce the phosphorylation of either STAT1 in RH/K30
FIG. 4. Time course of STAT protein phosphorylation in rabbit HTLV-1
ell lines. (A) Detection of STAT3 or phosphorylated STAT3 in RH/K30
ells treated with IL-10 (100 ng/ml) for up to 2 h (lanes a–f) compared
ith untreated RH/K34 cells (lane g) by immunoblotting. Densitometric
nalysis of induced phosphorylation of STAT3. Intensity is plotted as
elative units versus time of incubation. (B) Time course of IL-4- (25
g/ml) inducible STAT6 phosphorylation in RH/K34 cells (lanes a–f)
ompared with STAT6 phosphorylation in untreated RH/K30 cells (lane
). Densitometric analysis of induced phosphorylation of STAT6. Inten-
ity is plotted as relative units versus time of incubation.cells or STAT6 in RH/K34 cells; however, it did increase
the levels of phosphorylation of STAT1 and STAT6 (Figs.
5B and 5C). Surprisingly, IL-2 neither induced the phos-
phorylation of STAT3 in RH/K30 cells nor increased the
level of STAT3 phosphorylation in RH/K34 cells (Fig. 5D).
Addition of IL-15 induced STAT5 phosphorylation in a
manner similar to IL-2 (data not shown).
Inhibition of STAT protein phosphorylation by AG-490
Tyrphostin AG-490, a derivative of benzylidine malono-
nitrile, selectively blocks Jak2 and Jak3 kinases, but fails
to inhibit Jak1, Tyk2, or other tyrosine kinases expressed
in lymphocytes, including Lck, Lyn, Btk, Syk, Src, and Zap
70 (Meydan et al., 1996; Kirken et al., 2000). To assess
AG-490 inhibitory effects on the constitutive or induced
phosphorylation of Jak/STAT proteins, RH/K30 and RH/
K34 cells were treated with AG-490 for 16 h and stimu-
lated with the indicated cytokines. As shown in Fig. 6A, at
75 mM AG-490 markedly inhibited phosphorylation of
STAT6 in RH/K30 cells, but only slightly inhibited phos-
phorylation of STAT1 in RH/K34 cells (Fig. 6B). It had
FIG. 5. Effects of IL-2 treatment on phosphorylation of STAT proteins
in RH/K30 and RH/K34 cells. Cells were untreated or treated for 15 min
with 2 nM IL-2 and tested for the presence of tyrosine phosphorylated
(top) or native (bottom) STAT5 (A), STAT1 (B), STAT6 (C), or STAT3 (D) by
immunoblotting.almost no inhibitory effect on the phosphorylation of
STAT3 in RH/K34 (Fig. 6C). As expected, AG-490 could
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95CYTOKINE-INDUCED ACTIVATION OF HTLV-1 CELL LINESinhibit IL-4-induced phosphorylation of STAT6 in RH/K34
cells (Fig. 6A), while it had no effect on IL-10-induced
phosphorylation of STAT3 in RH/K30 cells (Fig. 6C).
These data indicate that the HTLV-1 lines studied here
utilize the conventional pathways of signal transduction
despite the unusual observation of activated STAT6 in
the RH/K30 cell line and the absence of the constitutive
activation of STAT5, which is expected for IL-2-indepen-
dent cell lines.
DISCUSSION
Abnormal STAT activation is a common feature of
many solid and hematologic malignancies, reflecting the
critical role of STAT proteins in regulating cell growth and
differentiation. Constitutive STAT activation has been re-
ported for HTLV-1-transformed cell lines and HTLV-1-
infected ATLL patients (Migone et al., 1995; Kirken et al.,
000; Collins et al., 1999; Zhang et al., 1999; Takemoto et
l., 1997). The present study provides evidence for dif-
erences in phosphorylation of STAT proteins in HTLV-1-
ransformed rabbit cell lines with demonstrated differ-
nces in their ability to cause leukemia-like disease. The
ell line RH/K30, which causes infection but no overt
isease, displayed constitutive phosphorylation of
FIG. 6. Specific inhibition of constitutive or induced STAT phosphor-
ylation by treatment with 75 mM AG-490. (A) RH/K30 or RH/K34 cells
retreated for 16 h with 75 mM AG-490 or with DMSO (control) were
tested for tyrosine-phosphorylated STAT6 in the presence or absence
of IL-4 (25 ng/ml). (B) RH/K34 cells were treated with 75 mM AG-490 or
DMSO solvent control for 16 h and tested for tyrosine-phosphorylated
STAT1. (C) RH/K30 or RH/K34 cells pretreated for 16 h with 75 mM
G-490 or with DMSO (control) were tested for tyrosine-phosphorylated
TAT3 in the presence or absence of IL-10 (100 ng/ml).TAT6; this has not been reported for other HTLV-1 cell
ines or for primary ATLL cells. The more conventionalattern of STAT1 and STAT3 phosphorylation was found
or the cell line RH/K34, which can cause lethal leukemia
n rabbits. In either cell line, the alternative Jak/STAT
ignaling pathway was readily activated by treatment
ith supernatants from the other cell line or by treatment
ith either IL-4 or IL-10. Surprisingly, STAT5, which is
ormally activated in HTLV-1 cells, is not phosphorylated
n the two cell lines unless they are treated with exoge-
ous IL-2. Both lines express IL-2Ra and IL-2Rgc.
A series of different cytokines is known to activate one
r more different STAT proteins. STAT6 is activated only
y IL-4 and IL-13, which share a receptor chain (Hou et
l., 1994). In contrast, STAT1, 3, 5A, and 5B are activated
y many different ligands (Darnell, 1997; Rane and
eddy, 2000; Akira, 2000). Expression of numerous cyto-
ines including IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-15,
NF-a, and GM-CSF has been reported in HTLV-1-in-
fected T-cells (Noma et al., 1989; Villiger et al., 1991; Mori
et al., 1996; Azimi et al., 1998). Of special relevance to the
present study are reports that serum IL-10 was detected
in 80% of the patients with acute ATLL, whereas it was
undetectable in most patients with chronic ATLL and in
asymptomatic carriers of HTLV-1 as well as in all healthy
blood donors tested (Mori et al., 1996; Mori and Prager,
1998). The IL-10 concentration correlated with the evolu-
tion of ATLL from the active phase to remission or from
the chronic to acute phase. Since IL-10 may be inhibitory
to the generation of antitumor immunity (Wang et al.,
1994; Beissert et al., 1995) the above reports suggest that
HTLV-1 cells producing IL-10 can escape host defenses
and mediate lethal disease. Our finding that IL-10 ex-
pression is upregulated in RH/K34 cells but not in RH/
K30 cells is in complete conformity with this possibility.
Mechanisms of IL-10 upregulation and whether it alone
leads to leukemogenesis in HTLV-1 infection require
further investigation.
If IL-10 is a hallmark of a lethal HTLV-1 cell, a question
arises concerning the role of IL-4 expression as seen in
RH/K30. Reports of IL-4 expression in HTLV-1-infected
cells have varied significantly. Noma et al. (1989) found
IL-4 expression in some ATLL cells transformed by
HTLV-1, while Mori et al. (1994) found no evidence of IL-4
mRNA expression in the freshly isolated leukemic cells
of 11 ATLL patients by RT-PCR. Shimamoto et al. (1996)
also showed that the peripheral blood mononuclear cells
(PBMCs) from HTLV-1 carriers consistently produced
large amounts of certain cytokines (IFN-g, IL-1a, TNF-a)
but not IL-4. Recent reports of sequences for rabbit
cytokines (Perkins et al., 2000) facilitated detection of the
IL-4 message in RH/K30 by RT-PCR. The present results
provide an opportunity to investigate the role of IL-4 in an
experimental model.
Specific cytokine/cytokine receptor combinations lead
to activation of the various STAT proteins. Therefore, the
interaction of a specific cytokine with its receptor in
HTLV-1 cell lines might maintain the phosphorylation of
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96 LIANG ET AL.STAT proteins. The following two lines of evidence sup-
port this possibility. First, the differing profiles of cytokine
expression correspond to the different patterns of phos-
phorylation of STAT proteins in RH/K30 and RH/K34 cell
lines. Second, results from FACS and RT-PCR reveal that
both RH/K30 and RH/K34 express IL-2Rgc, IL-4R, and
L-10R. Here we provide evidence that phosphorylation
f STAT3 in RH/K30 cells occurs in response to exoge-
ous IL-10 and that IL-4 induces the phosphorylation of
TAT6. IL-2 increased the phosphorylation level of STAT1
n RH/K34 cells and of STAT6 in RH/K30 cells but it
nduced neither the phosphorylation of STAT3 in RH/K30
ells nor that of STAT6 in RH/K34. These data differ from
tudies showing that STAT3 phosphorylation is associ-
ted with IL-2/IL-2R in HTLV-1 cells (Migone et al., 1995;
ollins et al., 1999; Zhang et al., 1999) and suggest that,
n addition to IL-2, other cytokines control HTLV-1-medi-
ted STAT activation. Since the IL-15 receptor has com-
onent chains in common with the IL-2 receptor, it is a
ikely candidate to substitute for IL-2. Preliminary studies
ndicate that both RH/K30 and RH/K34 express IL-15
RNA and that exogenous IL-15 had a similar effect on
he phosphorylation of STAT proteins as IL-2 (Liang and
ague, unpublished data).
In the time course experiment, either IL-4 or IL-10
timulated phosphorylation of the corresponding STAT in
s little as 5 min, suggesting that the STAT3 and STAT6
ignaling pathways are intact in both cell lines. Upon
ppropriate cytokine treatment alternative pathways can
e activated quickly in each cell line. These results
ncrease the possibility that cytokine treatment might
lter the phenotype of the distinct cell lines and further
lter their function.
The phosphorylation of STAT can be catalyzed by Jak
amily kinases, intrinsic receptor tyrosine kinases, and
ther cellular tyrosine kinases such as c-src (Lin et al.,
000). The well-documented kinases in HTLV-1 cells are
ak1 and Jak3 (Migone et al., 1995; Takemoto et al., 1997;
ulloy et al., 1998; Collins et al., 1999). In addition to
onstitutive phosphorylation of STAT1, STAT3, and STAT6,
e also found phosphorylation of Jak1 in both cell lines
y direct immunoblotting with antibody specific for ty-
osine-phosphorylated Jak1. Immunoprecipitation exper-
ments indicated that Jak1 associates with STAT1 and
TAT3 in RH/K34 cells, suggesting that Jak1 is the up-
tream kinase of STAT1 and STAT3. Surprisingly, STAT
roteins were also associated with Jak1 in RH/K30, al-
hough no phosphorylated STAT1 or 3 was detectable in
his cell line. Possible explanations for this include the
resence of negative regulators of STAT proteins such as
SI (STAT-induced STAT inhibitor) in RH/K30 cells that
ind to phosphorylated Jak1 to block its kinase effect on
TAT proteins (Losman et al., 1999; Sporri et al., 2001).
Another possibility is that phosphorylation of Jak1 may
not always cause phosphorylation of STAT1 and STAT3.
In a recent report, Zhang et al. (1999) found that Jak3 wasconstitutively phosphorylated but STAT5 was not in two
HTLV-1-transformed IL-2-independent cell lines. The
Jak2/3 inhibitor AG-490 inhibited not only the constitutive
phosphorylation of STAT6 in RH/K30 cells but also IL-4-
induced phosphorylation of STAT6 in RH/K34 cells. This
is difficult to explain because neither Jak2 nor Jak3 phos-
phorylation was seen in either of the rabbit cell lines. In
a similar situation, Nielsen et al. (1997) reported that
AG-490 could inhibit the constitutive phosphorylation of a
slowly migrating form of STAT3 in mycosis fungoides
cells and STAT3 was found to be associated with Jak3,
although Jak3 was not constitutively activated. They sug-
gest that Jak3 might be an important “docking” protein
rather than the initial activator and that malignant trans-
formation of mycosis fungoides cells involves either a
novel AG-490-sensitive kinase or an oncogenic form of a
known Jak protein. This result prompts further study of
the Jak3 proteins in rabbit HTLV-1 cells.
In conclusion, we have shown that the HTLV-1-trans-
formed cell lines with variable pathogenicity in vivo could
activate different Jak/STAT signaling pathways. Whether
the activation of STAT3- and STAT6-induced genes ex-
plains the variable pathogenic phenotypes in HTLV-1
infection is open to question. The fact that activation
status may be altered with cytokines will allow further
investigation of the relationship between cell activation
status and pathogenicity using the RH/K30 and RH/K34
cell lines in a well-established rabbit model for HTLV-1
infection and disease.
MATERIALS AND METHODS
Cell lines
The RH/K30 and RH/K34 cell lines were derived by
infection of rabbit PBMCs using the human HTLV-I-in-
fected cell line, MT-2. (Sawasdikosol et al., 1993). A3.01 is
a human T-cell leukemia cell line. All cell lines were
maintained in RPMI 1640 complete medium containing
10% fetal calf sera (FCS) (Invitrogen, Rockville, MD), 2
mM L-glutamine, penicillin (100 units/ml), and streptomy-
in (100 mg/ml).
etermination of cytokine and receptor expression
The expression of receptors for IL-10 and IL-4 was
etermined using biotinylated rhIL-4 or biotinylated
hIL-10 in the respective Fluorokine Cytokine Receptor
etection Kit (R&D Systems, Minneapolis, MN). In order
o determine the expression of IL-4, IL-10, and IL-2Rgc
genes in the cell lines RH/K30 and RH/K34, RT-PCR was
performed. Total RNA was isolated using the Trizol re-
agent (Invitrogen, Rockville, MD). First-strand cDNA was
oligo(dT) primed and synthesized using 100 units M-MLV
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97CYTOKINE-INDUCED ACTIVATION OF HTLV-1 CELL LINESreverse transcriptase (Invitrogen) in a reaction mix con-
taining 50 mM Tris–HCl, 75 mM KCl, 3 mM MgCl2, and 10
mM DTT. The PCR mixture contained a total volume of 10
ml: 10 mM Tris–HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2,
0.001% (wt/vol) gelatin; 3.5% glycerol; 0.2 mM dNTP; a 0.5
mM concentration of each forward and reverse primer; 1
ml (0.33 U) of Taq DNA polymerase (Perkin–Elmer, Nor-
walk, CT); and 1 ml (0.2–0.5 mg) of cDNA. Primer se-
quences were as follows: IL-10 F: 59 GTG AAG ACT TTC
TTT CAA ATC AAG G39; IL-10 R: 59GTT GAT GAA GAT
GTC AAA CTC39; IL-4 F: 59ACA TCA TCC TAC CCG
AAG39; IL-4 R: 59AAT ATT CAG CTC TGA CGC39; IL-2Rgc
: 59GCC ATG TTG AAG CCA TCA TTA CCA39; IL-2Rgc R:
59TCA GGT TTC AGG CTT TAG GGT39. The primers
b-actin F (59TAC ATG GCT GGG GTG TTG AA39) and
b-actin R (59AAG AGA GGC ATC CTC ACC CT39) were
included in all PCRs to amplify an internal positive con-
trol PCR product, a 218-bp fragment of b-actin. After
enaturation for 5 min at 95°C, cDNA samples were
ubjected to 35 cycles of PCR in a DNA Thermal
ycler. Each cycle included 95°C for 30 s, 57°C for
0 s, and 72°C for 1.5 min followed by a final extension
t 72°C for 5 min. PCR products were analyzed by
lectrophoresis on a 2% agarose gel containing 0.5
mg/ml ethidium bromide and then visualized using UV
ransillumination.
ell treatment and cell lysate preparation
For the AG-490 inhibition experiment, cells were pre-
reated with varying concentrations of AG-490 (Calbio-
hem, La Jolla, CA) or DMSO as control for 16 h in RPMI
640 medium with 1% FCS before exposure to cytokines.
ells were then stimulated with different cytokines as
escribed in the figure legends. To test cytokine induc-
ive effect, cells were washed once in serum-free RPMI
640 medium and incubated in serum-free RPMI 1640
edium for 20–24 h. The next day, the cells were stim-
lated with 2 nM hrIL-2 (Calbiochem) for 15 min at 37°C
r 25 ng/ml of hrIL-4 (Calbiochem) or 100 ng/ml of hrIL-10
R&D Systems Inc.) for different time points at 37°C in 4
l serum-free RPMI medium. After stimulation, cells
ere washed two times in cold PBS and lysed in 0.2 ml
f lysis buffer containing 150 mM NaCl, 1% Triton X-100,
.1% SDS, 50 mM Tris–HCl, pH 7.4, protease inhibitor
ocktail tablet (Roche, Indianapolis, IN), and phospha-
ase inhibitor cocktail (Sigma Co., St. Louis, MO) at 4°C
ith end-over-end shaking for 30 min. Samples were
hen centrifuged for 10 min at 13,000 rpm at 4°C, super-
atants were transferred to a clean tube, and pellets
ere discarded. Protein concentration was measured
ith the DC protein assay kit (Bio-Rad, Hercules, CA).
amples were diluted to 2 mg/ml with the above lysis
uffer and stored at 280°C or directly used for immuno-
lotting.mmunoprecipitation and immunoblotting
For immunoprecipitation, samples were precleared
ith protein A–agarose (KPL, Gaithersburg, MD) for 1 h
t 4°C. Beads were pelleted by centrifugation at 13,000
pm for 1 min and supernatants were transferred to a
resh tube at 4°C. Primary antibody agarose conjugates
Santa Cruz Biotechnology Inc., Santa Cruz, CA) were
dded to supernatants and the mixture was incubated at
°C overnight with end-over-end rotation. Next, samples
ere centrifuged at 13,000 rpm for 1 min at 4°C and
upernatants were removed. The beads were then
ashed three times with 1 ml of the above lysis buffer
ithout protease inhibitor. Following washing, 40 ml of
23 SDS sample buffer (Invitrogen) was added with 5%
2-ME and samples were heated for 4 min at 95°C.
Supernatants were then collected by centrifugation and
20 ml was loaded to the precast gel.
For the direct immunoblotting, the samples were
hawed on ice, mixed with 63 SDS sample buffer (0.35 M
ris–HCl (pH 6.8), 10% SDS, 36% glycerol, 0.025% bromo-
henol blue, 5% 2-ME), and heated at 95°C for 4 min;
0-ml aliquots were then loaded to a precast Tris glycine
el (Invitrogen) and separated by SDS–PAGE at 130 V for
.5 h. Following electrophoresis, proteins were trans-
erred to Immobilon P membranes (Millipore, Bedford,
A) at 100 mA for 1.5 h. The membranes were incubated
n blocking buffer containing PBS, 0.05% Tween 20, and
% nonfat milk and then probed with specific primary
ntibodies for 2 h at room temperature or overnight at
°C. Antibodies to STAT1, STAT3, STAT5, and STAT6 were
urchased from Transduction Laboratories (Lexington,
Y). Anti-Jak1 or anti-phosphotyrosine Jak1 antibodies
ere from Biosource International (Camarillo, CA). Anti-
hosphotyrosine STAT3 was obtained from Upstate Bio-
echnology Inc. (Lake Placid, NY). Anti-phosphotyrosine
TAT1, STAT5, and STAT6 were purchased from New
ngland Biolabs Inc. (Beverly, MA). Membranes were
insed in PBST buffer (0.05% Tween 20 in PBS) for 53 5
in and incubated with horseradish peroxidase-conju-
ated secondary antibody (Southern Biotechnology As-
ociates, Birmingham, AL). Membranes were rinsed
gain for 53 5 min in PBST buffer and developed with the
nhanced chemiluminescence (ECL) immunoblotting
ystem (Amersham Pharmacia Biotech, Piscataway, NJ).
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